

# Evaluating Diuretics in Normal Care (EVIDENCE) - a cluster randomised evaluation of hypertension prescribing policy

<b>Submission date</b> 09/08/2017	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 11/08/2017	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 20/01/2025	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Having high blood pressure increases the chances that a person will suffer a heart attack or stroke in the future. The aim of treating high blood pressure with medication is to reduce this risk. A number of different types of medication are known to be effective in reducing blood pressure and in reducing the risk of heart attack and stroke. One of these medication types is the diuretics, often referred to as “water-tablets”. There are two diuretics commonly used in the UK for the treatment of high blood pressure but we do not know which is better. We know that they both work but one may be more effective than the other in the long term. The EVIDENCE (Evaluating Diuretics in Normal Care) study aims to find out if one of these medications is better than the other at preventing heart attacks and strokes. In everyday practice, GP's and hospital doctors are guided by agreed policies, based upon the best available evidence, in deciding which medications are likely to be the most effective. This study aims to compare the effectiveness of two different prescribing policies for diuretics in preventing heart attacks and strokes.

### Who can participate?

Patients aged 18 and older who are diagnosed with a thiazide, or thiazide-like diuretic to treat hypertension.

### What does the study involve?

Participating GPs are randomly assigned to one of these two prescribing policies. The doctors within that practice then use that policy to guide their prescribing decisions. As already happens in the NHS, mechanisms for switching from one medication to another is used to help practices adhere to their prescribing policy. GP's and their patients are free to choose what they think is the most appropriate treatment in each individual case. People who are registered in practices taking part in the study have their blood pressure medication managed by their GP in the usual way. If the practice policy requires a change to a patient's usual diuretic prescription, participants are sent a letter advising them that this will take effect on their next requested prescription. All such patients will be given the opportunity to decline the switch. Participants are followed up with for the cardiovascular outcomes.

What are the possible benefits and risks of participating?

As the two medications in question are currently thought to be effectively the same in terms of benefits and side effects, there will be no direct risk or benefit to a person whose GP practice is taking part in the study.

Where is the study run from?

Medicines Monitoring Unit, University of Dundee (UK)

When is the study starting and how long is it expected to run for?

October 2017 to December 2025

Who is funding the study?

University of Dundee (UK)

Who is the main contact?

Dr Amy Rogers

[arogers@dundee.ac.uk](mailto:arogers@dundee.ac.uk)

## Contact information

### Type(s)

Public

### Contact name

Dr Amy Rogers

### ORCID ID

<https://orcid.org/0000-0001-5207-7032>

### Contact details

Medicines Monitoring Unit

University of Dundee

Medical School

Dundee

United Kingdom

DD1 9SY

+44 1382 383390

[arogers@dundee.ac.uk](mailto:arogers@dundee.ac.uk)

## Additional identifiers

### Integrated Research Application System (IRAS)

219202

### Protocol serial number

Protocol number: 2016CV12

## Study information

### Scientific Title

Evaluating Diuretics in Normal Care (EVIDENCE) - a cluster randomised evaluation of hypertension prescribing policy

## Acronym

EVIDENCE

## Study objectives

The aim of this study is to formally evaluate the effectiveness of a policy of prescribing bendroflumethiazide versus a policy of prescribing indapamide as first-line choice of thiazide /thiazide-like diuretic in the treatment of hypertension.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved 04/01/2017, East of Scotland Research Ethics Service (EoSRES) (Tayside Medical Science Centre (TASC), Ninewells Hospital and Medical School, Dundee, DD1 9SY, United Kingdom; 01382 383878; tay.eosres@nhs.scot), ref: 219202 17/ES/0016

## Study design

Two-arm cluster randomized study of prescribing policy

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Hypertension and cardiovascular risk

## Interventions

Current interventions as of 27/02/2020:

There are two study arms. Practices are randomly assigned on a 1:1 basis (using a computer algorithm) to either of two prescribing policies:

1. A policy of using Bendroflumethiazide (2.5mg, oral, once daily) as first choice when a diuretic is required for the treatment of hypertension
2. A policy of using Indapamide (2.5mg, immediate release, oral, once daily) as first choice when a diuretic is required for the treatment of hypertension

Practices agreed to adopt the assigned policy for future prescribing and existing routine prescriptions are been switched accordingly. Doctors remain free to select the most appropriate medication for their patients.

All patients eligible for a potential medication switch are informed by letter of the policy change. The letter explains the reason for any medication changes and directs patients to visit the study website or contact the study team (by telephone or email) to find out more about the study or to opt-out of the proposed medication change.

---

Previous interventions:

There are two study arms. Practices are randomly assigned on a 1:1 basis (using a computer algorithm) to either of two prescribing policies:

1. A policy of using Bendroflumethiazide (2.5mg, oral, once daily) as first choice when a diuretic is required for the treatment of hypertension
2. A policy of using Indapamide (2.5mg, immediate release, oral, once daily) as first choice when a diuretic is required for the treatment of hypertension

Individual treatment decisions regarding drug choice, dosage, method and frequency of administration for patients will be left up to the treating GPs.

Where patients are already taking thiazide, or thiazide-like, diuretics at the time a practice joins the study, routine repeat prescriptions will be switched to the policy preferred drug, unless clinically indicated.

### **Intervention Type**

Other

### **Primary outcome(s)**

The composite cardiovascular outcome (comprising non-fatal MI, non-fatal stroke, hospitalization for congestive heart failure, and vascular death) is measured using electronic record-linkage to national datasets of routinely collected data and supported by information from medical records.

### **Key secondary outcome(s)**

1. Each individual component of the composite primary outcome will be included as a secondary outcome
2. All-cause mortality is measured using record-linkage to national datasets of routinely collected data

The study is primary outcome driven so the outcomes are counted as they occur rather than at defined time periods. We expect that the follow-up process will take around 3 years to accrue sufficient events to power the study.

### **Completion date**

31/12/2025

## **Eligibility**

### **Key inclusion criteria**

1. Registered patients with a documented diagnosis of hypertension and prescribed a thiazide, or thiazide-like, diuretic in a participating practice
2. Aged 18 years and older

### **Participant type(s)**

Other

### **Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Total final enrolment**

98

**Key exclusion criteria**

Does not meet the inclusion criteria

**Date of first enrolment**

01/10/2017

**Date of final enrolment**

31/07/2023

**Locations****Countries of recruitment**

United Kingdom

Scotland

**Study participating centre****Medicines Monitoring Unit**

University of Dundee

Ninewells Hospital and Medical School

Dundee

United Kingdom

DD1 9SY

**Sponsor information****Organisation**

University of Dundee/NHS Tayside

**ROR**

<https://ror.org/03h2bxq36>

# Funder(s)

## Funder type

Research council

## Funder Name

Medicines Monitoring Unit University of Dundee

# Results and Publications

## Individual participant data (IPD) sharing plan

Current IPD sharing statement as of 11/11/2022:

The datasets generated during and/or analysed during the current study are not expected to be made available because these are anonymised clinical data sets that must be analysed in a secure SAFE HAVEN accessed only by Public Benefit and Privacy Panel (PBPP)-approved individuals and therefore cannot be made publicly available. Only summary statistics (in a publication) will be presented.

Previous IPD:

The data sharing plans for the current study are unknown and will be made available at a later date.

## IPD sharing plan summary

Not expected to be made available

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>		17/11/2021	31/01/2022	Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Interim results article</a>	feasibility report	11/03/2022	14/03/2022	Yes	No
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes